Interaction of mammalian cells with polymorphonuclear leukocytes: relative sensitivity to monolayer disruption and killing.
Monolayers of murine fibrosarcoma cells that had been treated either with histone-opsonized streptococci, histone-opsonized Candida globerata, or lipoteichoic acid-anti-lipoteichoic acid complexes underwent disruption when incubated with human polymorphonuclear leukocytes (PMNs). Although the architecture of the monolayers was destroyed, the target cells were not killed. The destruction of the monolayers was totally inhibited by proteinase inhibitors, suggesting that the detachment of the cells from the monolayers and aggregation in suspension were induced by proteinases releases from the activated PMNs. Monolayers of normal endothelial cells and fibroblasts were much resistant to the monolayer-disrupting effects of the PMNs than were the fibrosarcoma cells. Although the fibrosarcoma cells were resistant to killing by PMNs, killing was promoted by the addition of sodium azide (a catalase inhibitor). This suggests that the failure of the PMNs to kill the target cells was due to catalase inhibition of the hydrogen peroxide produced by the activated PMNs. Target cell killing that occurred in the presence of sodium azide was reduced by the addition of a "cocktail" containing methionine, histidine, and deferoxamine mesylate, suggesting that hydroxyl radicals but not myeloperoxidase-catalyzed products were responsible for cell killing. The relative ease with which the murine fibrosarcoma cells can be released from their substratum by the action of PMNs, coupled with their insensitivity to PMN-mediated killing, may explain why the presence of large numbers of PMNs at the site of tumors produced in experimental animals by the fibrosarcoma cells is associated with an unfavorable outcome.
Ginsburg
I
I
Department of Oral Biology, Hebrew University-Hadassah School of Dental Medicine, Jerusalem, Israel.
Gibbs
D F
DF
Varani
J
J
D000818:Animals; D001386:Azides / Q000494:pharmacology; D002175:Candida / Q000502:physiology; D002374:Catalase / Q000037:antagonists & inhibitors; D002448:Cell Adhesion; D002470:Cell Survival; D003602:Cytotoxicity, Immunologic; D005354:Fibrosarcoma / Q000473:pathology*; D005609:Free Radicals; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D009504:Neutrophils / Q000502:physiology*; D009895:Opsonin Proteins / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D019810:Sodium Azide; D013291:Streptococcus / Q000502:physiology; D013682:Teichoic Acids / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects
D001386:Azides; D005609:Free Radicals; D008070:Lipopolysaccharides; D009895:Opsonin Proteins; D011480:Protease Inhibitors; D013682:Teichoic Acids; C009900:lipoteichoic acid; D019810:Sodium Azide; D002374:Catalase